Hernán Villota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hernán Villota has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alvaro Delgadillo
Universidad de La Serena
1 shared publication - Fabian Mauricio Cortés-Mancera
Grupo de Gastrohepatología, Sede de Investigación Universitaria SIU, Universidad de Antioquia, Medellín 050010, Colombia
1 shared publication - Francisco Gajardo
Departamento de Química, Facultad de Ciencias, Universidad de La Serena, Benavente 980, La Serena, Chile
1 shared publication - Giuliano Bernal
Laboratory of Molecular and Cellular Biology of Cancer, CáncerLab, Department of Biomedical Sciences, Faculty of Medicine, Universidad Católica del Norte, Coquimbo, Chile
1 shared publication - Sebastián Pizarro
Universidad de La Serena
1 shared publication
Latest Publications
- 13 August 2019
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 51 (2) , 571-578
Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells
Purpose In this work, we present a recently developed ruthenium complex that shows anticancer activity in gallbladder cancer cells. Methods After the synthesis of the new ruthenium complexes, the antiproliferative, cytotoxicity, and apoptosis activities were evaluated in vitro by the triple assay ApoTox-Glo. Then, the transcription levels of genes related to apoptosis were evaluated by real-time PCR (q-PCR). Results The ruthenium complex, called Ru-UCN3, inhibits the proliferation of gallbladder cancer cells G-415 by means of apoptosis, which was demonstrated by the overexpression of the pro-apoptotic genes Puma, Diablo, and Caspasa-9 together with the repression of the anti-apoptotic genes Bcl-xL and Bcl-2. In addition, we found strong caspase 3/7 activity in the cells at 24 h of the Ru-UCN3 exposure, which was evaluated by the triple ApoTox-Glo assay. Conclusion The new ruthenium complexes evaluated had an inhibitory effect on G-415 cells. We think that Ru-UCN3 could be a promising anticancer agent, which should be explored with more in vitro and in vivo assays and probably with the chemical modulation of this molecule.
- 13 August 2019
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 51 (2) , 571-578
Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells
Purpose In this work, we present a recently developed ruthenium complex that shows anticancer activity in gallbladder cancer cells. Methods After the synthesis of the new ruthenium complexes, the antiproliferative, cytotoxicity, and apoptosis activities were evaluated in vitro by the triple assay ApoTox-Glo. Then, the transcription levels of genes related to apoptosis were evaluated by real-time PCR (q-PCR). Results The ruthenium complex, called Ru-UCN3, inhibits the proliferation of gallbladder cancer cells G-415 by means of apoptosis, which was demonstrated by the overexpression of the pro-apoptotic genes Puma, Diablo, and Caspasa-9 together with the repression of the anti-apoptotic genes Bcl-xL and Bcl-2. In addition, we found strong caspase 3/7 activity in the cells at 24 h of the Ru-UCN3 exposure, which was evaluated by the triple ApoTox-Glo assay. Conclusion The new ruthenium complexes evaluated had an inhibitory effect on G-415 cells. We think that Ru-UCN3 could be a promising anticancer agent, which should be explored with more in vitro and in vivo assays and probably with the chemical modulation of this molecule.